747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors by Joal D Beane, Yazan Samhouri, Brent A Hanks, John Hyngstrom, Sarah Weiss, Heidi Gillenwater, Yeonhee Kim, J Randolph Hecht, Bishwa J Ganguly, Hajime Hiraragi, Lucy Gong, Navid Nikoo